Navigation Links
NeurogesX to Report Second Quarter 2008 Financial Results
Date:8/5/2008

chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
(Date:12/19/2014)... -- Bina Technologies, Inc. (Bina, Redwood City, ... been acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY).  ... that provides a big data platform for centralized management ... the academic and translational research markets.  Bina will be ... to focus on development of their innovative genomic analysis ...
(Date:12/19/2014)... , Dec. 19, 2014 Research and ... the addition of the "Technology Innovations in ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in Smart Fabrics" offers a detailed assessment on ... Key Findings: 1. The ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... Platteville, Wis. - The University of ... involved in a new online certificate program offered ... announced on Wednesday. , ,The Project Management Certificate ... training and education programs necessary for advancement in ...
... Wis. -- It goes without saying: Life often ... a prominent scientist, leader and manager in the pharmaceutical ... following a highly successful and fulfilling career. After nearly ... development in companies both big and small in Connecticut, ...
... and, in reality too, as an ultra-sophisticated, digitally ... agendas in shapes of large digital cyber-warfare torpedoes ... and direct hits took over. , ,Now there ... are either corporate elites or very smart solo ...
Cached Biology Technology:Van Campen reviving UW's drug-development related education 2Van Campen reviving UW's drug-development related education 3Van Campen reviving UW's drug-development related education 4Van Campen reviving UW's drug-development related education 5Van Campen reviving UW's drug-development related education 6Cyber-skating on one flat earth 2Cyber-skating on one flat earth 3Cyber-skating on one flat earth 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... the Journal of Biological Chemistry identifies a new ... Children,s Hospital Medical Center, the research shows that expression of ... in mouse models. The study appears in the journal,s Aug. ... depletion of FoxM1 in prostate epithelial cells inhibits tumor cell ...
... clinical study, researchers administered a new method for treating ... be worn like a band-aid. The applicator delivers low-frequency, ... significantly accelerate healing in five patients with venous ulcers. ... malfunction, causing blood to pool in the leg instead ...
... largest yearly gathering of research cell biologists along ... scientists from other disciplines, all drawn by the ... The ASCB,s online press book, "Cell Biology ... top picks for breaking science news. For embargoed ...
Cached Biology News:Ultrasound patch heals venous ulcers in human trial 2Ultrasound patch heals venous ulcers in human trial 3Ultrasound patch heals venous ulcers in human trial 4
... cocktail is tailored to highly ... suspensions of non-human primate (Rhesus ... using the StemSep compatible 0.5 ... The CD4+ T cell content ...
... 4100 high pressure dual piston pump and the ... for added flexibility. The system is provided ... CE 4901., The CE 4901 PowerStream software operating ... Windows 98 and 2000, offers the same data ...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Biology Products: